| Date | Acquired company | Acquiring company | Amount | Related |
|---|---|---|---|---|
| 2015-02-24 | Meritage Pharma (USA - CA) | Shire (UK - USA) | $70 million and additional contingent payments based on the achievement of development and regulatory milestones | Rare diseases Gastrointestinal diseases |
| 2015-02-24 | Canbex Therapeutics (UK) | Ipsen (France) | up to €96 million | Neurodegenerative diseases |
| 2015-02-23 | Heptares Therapeutics (UK) | Sosei (Japan) | up to $ 400 million | Metabolic diseases Neurologic diseases Neurodegenerative diseases Rare diseases |
| 2015-02-16 | CFL GmbH, a Fresenius Kabi subsidiary (Germany) | NewCo Pharma (Germany) | undisclosed | Cancer - Oncology |
| 2015-02-13 | ActoGenix (Belgium) | Intrexon (USA - MD) | $ 60 million | Gastrointestinal diseases Immunological diseases Metabolic diseases Synthetic biology |
| 2015-02-11 | Glycovaxyn (Switzerland) | GSK (UK) | $190 million | Infectious diseases |
| 2015-02-10 | Dendreon (USA - WA) | Valeant Pharmaceuticals (Canada) | $296 million | |
| 2015-02-09 | Signature Diagnostics (Germany) | Roche (Switzerland) | undisclosed | Diagnostic Technology - Services |
| 2015-02-05 | Advanced Scientifics (USA - PA) | Thermo Fisher Scientific (USA - MA) | $300 million | Technology - Services Bioproduction - Manufacturing |
| 2015-02-04 | Annovation Biopharma (USA - MA) | The Medicines Company (USA - NJ) | undisclosed | Critical care |
| 2015-02-04 | Cytune Pharma (France) | Sotio (Czech Republic) PPF Group (Czech Republic) | undisclosed | Cancer - Oncology Infectious diseases |
| 2015-02-02 | MediMedia Pharma Solutions (USA - PA) | Icon (Ireland) | $120 million | CRO Technology - Services |
| 2015-02-02 | MacuVision Europe (UK) | Alliance Pharma (UK) | up to £6.0 million | Ophtalmological diseases |
| 2015-01-26 | SEPS Pharma (Belgium) | Amatsi group (France) | undisclosed | |
| 2015-01-21 | Firefly BioWorks (USA - MA) | Abcam (UK) | £18.5 million (€24.1 million) | Technology - Services |
| 2015-01-16 | Trophos (France) | Roche (Switzerland) | up to €470 million | Rare diseases - Neuromuscular diseases |
| 2015-01-13 | Enzyme Solutions Unit of Enzymatics (USA - CA) | Qiagen (The Netherlands) | undisclosed | Technology - Services |
| 2015-01-11 | NPS Pharma (USA - NJ) | Shire (UK - USA) | $5.2 billion (€4.4 billion) | Rare diseases |
| 2015-01-11 | Convergence Pharmaceuticals (UK) | BiogenIdec (USA - MA) | up to $475 million | Rare diseases CNS diseases |
| 2015-01-08 | Haplogen Genomics (Austria) | Horizon Discovery (UK) | £6 million (€7.7 million) | Technology - Services |
